By downregulating Toll-like receptor 4 (TLR4) and activating the Akt/PTEN signaling pathway, Cav-1 reduces RGC apoptosis, underscoring its potential as a novel therapeutic target for glaucoma [208]. This evidence concerns the gene TLR4 and glaucoma.